Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, National, Multi-centric, Non-interventional Study of First Line Osimertinib in Chinese Patients With Locally Advanced/Metastatic EGFR Mutation-positive NSCLC in Real World Setting

Next Previous
Trial Profile

A Prospective, National, Multi-centric, Non-interventional Study of First Line Osimertinib in Chinese Patients With Locally Advanced/Metastatic EGFR Mutation-positive NSCLC in Real World Setting

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FLOURISH

Most Recent Events

  • 16 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
  • 16 Mar 2023 Status changed from recruiting to active, no longer recruiting.
  • 13 Sep 2022 Interim results (at data cut-off: 23 Mar 2022; n=96) assessing efficacy and safety of first-line therapy of osimertinib in non-small cell lung cancer patients, presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top